Melting points were determined using a Büchi-Tottoli apparatus. 1 H and 13 C NMR spectra were recorded in CDCl 3 , DMSO-d 6 and solution (unless otherwise specified) with TMS as an internal reference using a Bruker AC 300 ( 1 H) or 75MHz ( 13 C) instruments. Chemical shifts are given in δ parts per million (ppm) downfield from TMS. Multiplicities of 13 C NMR resources were assigned by distortionless enhancement by polarization transfer (DEPT) experiments. Low-resolution mass spectra (MS) were recorded on a Perkin-Elmer Sciex API 3000 spectrometer. Column chromatography was carried out on SiO 2 (silica gel 60 Merck 0.063-0.200 mm). Thin-layer chromatography (TLC) was carried out on SiO 2 (silica gel 60, F 254 Merck 0.063-0.200 mm), and the spots were located with UV light. Commercial reagents were used without further purification unless stated.
acetate (50 mL x 3). The combined organic extracts were dried over MgSO 4 , filtered, and concentrated. The residue was purified by column chromatography on silica gel using ethyl acetate/hexane (3:7) to afford the desired products in good yields. 1 H NMR, 13 CNMR and DEPT copies of selected compounds are given in the supporting information. C, 65.58; H, 5.50; N, 13.50. Found: C, 65.67; H, 5.42; N, 13.64 .
3-(1-
(
3-(1-(1-Ethyl-1H-indazol-6-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione
3-(1-(2-Ethyl-2H-indazol-6-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione (6b 
3-(1-(2-Ethyl-2H-indazol-5-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione

3-(1-(1-Allyl-1H-indazol-5-ylamino)ethylidene)-6-methyl-3H-pyran-2,4-dione
Biology Parasite and cell cultures. Promastigotes of the Leishmania donovani
(MHOM/ET/67/HU3/LV9) were cultured in the dark at 26°C with 5% CO 2 in M199 complete medium containing M199 medium supplemented with 100 μM adenosine, 0.5 mg/L hemin, 40 mM Hepes pH 7.4 and 10 % heat inactivated foetal bovine serum (HIFBS). Cultures of axenic amastigotes of L. donovani were obtained from late log promastigotes diluted at 1 x 10 6 /mL in M199 complete medium acidified at pH 5.5 and cultured at 37°C with 5% CO 2 .
Macrophage. The macrophages RAW 264.7 were cultured at 37°C with 5% CO 2 in DMEM complete medium containing Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 100 U/mL penicillin-streptomycin, and 10% HIFBS.
Evaluation of compounds cytotoxicity. Cytotoxicity was evaluated on RAW 264.7
macrophages. Cells were plated in 96-well microplates at a density of 2 x 10 4 cells per well.
After an incubation of 24 h at 37°C with 5% CO 2 , the medium was removed in each well, and 100 μl of DMEM complete medium containing two fold serial dilutions of the compounds was added to each well. After 48 h of incubation at 37°C with 5% CO 2 , 10 μl of resazurin (450 μM) was added to each well, and further incubated in the dark for 4 h at 37°C with 5% CO 2 . Cell viability was then monitored as described above. The cytotoxicity of the compounds was expressed as CC50 (Cytotoxic Concentration 50%: concentration inhibiting the macrophages growth by 50%).
In vitro antileishmanial evaluation of compounds on axenic and intramacrophage amastigotes. The evaluations of activity on axenic and intramacrophage amastigotes of L.
donovani were adapted from the protocols previously described [19] . Briefly, for the evaluation on axenic amastigotes, two fold serial dilutions of the compounds were performed in 100 μl of complete medium (see above) in 96-well microplates. Axenic amastigotes were then added to each well at a density of 10 6 /ml in a 200 μl final volume. After 72 h of incubation at 37°C with 5 % CO 2 , 20 μl of resazurin (450 μM) was added to each well and further incubated in the dark for 24 h at 37°C with 5% CO 2 . In living cells, resazurin is reduced in resorufin and this conversion is monitored by measuring OD570nm (resorufin) and OD600nm (resazurin; Lab systems Multiskan MS). The activity of the compounds was expressed as IC 50 in µM. Amphotericin B (AmB) was used as the reference drug.
Concerning the evaluation on intramacrophage amastigotes, RAW 264.7 macrophages were plated in 96-well microplates at a density of 2 x 104 cells per well and incubated for 24 h at 37°C with 5% CO2. Axenic amastigotes were differenciated as described above, centrifuged at 2,000 g for 10 min, resuspended in DMEM complete medium, and added to each well to reach a 16 :1 parasite to macrophage ratio. After 24 h of infection at 37°C with 5% CO 2 , extracellular parasites were removed, and DMEM complete medium (100 μl) containing two fold serial dilutions of the compounds from a maximal concentration of 100 μM was added to each well. After 48 h of treatment, the medium was removed and replaced by Direct PCR Lysis Reagent (100 μl; Euromedex) before 3 freeze-thaw cycles at room temperature, addition of 50 μg/ml proteinase K, and a final incubation at 55°C overnight to allow cell lysis. 10 μl of each cell extract was then added to 40 μl of Direct PCR Lysis reagent containing Sybr Green I (0.05%; Invitrogen). DNA fluorescence was monitored using Mastercycler® realplex (Eppendorf). The activity of the compounds was expressed as IC 50 in µM. Amphotericin B (AmB) was used as the reference drug.
Selected 1 H NMR, 13 C NMR and DEPT spectra of compounds 5a-d, 5g, 6b-e, 9a-c, 10a and 10b. Figure S1 . 1 H NMR, 13 C NMR and DEPT spectra of compound 5a P9-P10 Figure S2 . 1 H NMR, 13 C NMR and DEPT spectra of compound 5b P10-P11 Figure S3 . 1 H NMR, 13 C NMR and DEPT spectra of compound 6b P12-P13 Figure S4 . 1 H NMR, 13 C NMR and DEPT spectra of compound 5c P13-P14 Figure S5 . 1 H NMR, 13 C NMR and DEPT spectra of compound 6c P15-P16 Figure S6 . 1 H NMR, 13 C NMR and DEPT spectra of compound 5d P16-P17 Figure S7 . 1 H NMR, 13 C NMR and DEPT spectra of compound 6d P18-P19 Figure S8 . 1 H NMR, 13 C NMR and DEPT spectra of compound 6e P19-P20 Figure S9 . 1 H NMR, 13 C NMR and DEPT spectra of compound 5g P21-P22 Figure S10 . 1 H NMR, 13 C NMR and DEPT spectra of compound 9a P22-P23 Figure S11 . 1 H NMR, 13 C NMR and DEPT spectra of compound 10a P24-P25 Figure S12 . 1 H NMR, 13 C NMR and DEPT spectra of compound 9b P25-P26 Figure S13 . 1 H NMR, 13 C NMR and DEPT spectra of compound 10b P27-P28 Figure S14 . 1 H NMR, 13 C NMR and DEPT spectra of compound 9c P28-P29 Figure S1 . 1 H NMR (300 MHz, DMSO-d 6 ) spectra of compound 5a
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